Technical Analysis for ANIX - Anixa Biosciences, Inc.

Grade Last Price % Change Price Change
D 3.51 -4.88% -0.18
ANIX closed down 4.88 percent on Monday, March 18, 2024, on 66 percent of normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish 0.00%
Slingshot Bearish Bearish Swing Setup -4.88%
Crossed Above 20 DMA Bullish -4.88%
Crossed Above 200 DMA Bullish -4.88%
MACD Bullish Signal Line Cross Bullish -4.88%
New Uptrend Bullish -4.88%
Stochastic Buy Signal Bullish -4.88%
Pocket Pivot Bullish Swing Setup -4.88%
Wide Range Bar Range Expansion -4.88%
Gapped Up Strength -4.88%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 14 hours ago
200 DMA Support about 17 hours ago
1.5x Volume Pace about 17 hours ago
Rose Above Previous Day's High about 17 hours ago
Down 3% about 17 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Anixa, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer. Anixa is developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed. It is developing the CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. It is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. Anixa also continually examines emerging technologies in complementary or related fields for further development and commercialization.
Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immune System Emerging Technologies Cancer Treatment Gene Therapy Leukemia Blood Test Amines Chimeric Antigen Receptor Immune Response

Is ANIX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 6.45
52 Week Low 2.75
Average Volume 151,674
200-Day Moving Average 3.59
50-Day Moving Average 4.08
20-Day Moving Average 3.48
10-Day Moving Average 3.35
Average True Range 0.27
RSI (14) 46.52
ADX 33.08
+DI 21.73
-DI 19.64
Chandelier Exit (Long, 3 ATRs) 3.55
Chandelier Exit (Short, 3 ATRs) 3.81
Upper Bollinger Bands 3.90
Lower Bollinger Band 3.05
Percent B (%b) 0.54
BandWidth 24.29
MACD Line -0.20
MACD Signal Line -0.23
MACD Histogram 0.0291
Fundamentals Value
Market Cap 111.27 Million
Num Shares 31.7 Million
EPS -0.32
Price-to-Earnings (P/E) Ratio -10.97
Price-to-Sales 680.79
Price-to-Book 5.87
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.95
Resistance 3 (R3) 3.99 3.90 3.87
Resistance 2 (R2) 3.90 3.79 3.87 3.85
Resistance 1 (R1) 3.70 3.72 3.66 3.66 3.82
Pivot Point 3.61 3.61 3.58 3.58 3.61
Support 1 (S1) 3.41 3.50 3.37 3.37 3.20
Support 2 (S2) 3.32 3.43 3.29 3.17
Support 3 (S3) 3.12 3.32 3.15
Support 4 (S4) 3.08